Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 3
1946 1
1947 5
1948 2
1949 5
1950 4
1951 12
1952 13
1953 13
1954 17
1955 10
1956 9
1957 9
1958 14
1959 12
1960 16
1961 20
1962 16
1963 14
1964 14
1965 10
1966 20
1967 34
1968 34
1969 33
1970 35
1971 31
1972 33
1973 38
1974 33
1975 56
1976 37
1977 56
1978 45
1979 56
1980 57
1981 56
1982 66
1983 65
1984 76
1985 94
1986 94
1987 91
1988 110
1989 120
1990 135
1991 144
1992 133
1993 151
1994 158
1995 154
1996 164
1997 149
1998 154
1999 153
2000 182
2001 196
2002 220
2003 213
2004 213
2005 301
2006 334
2007 365
2008 311
2009 340
2010 366
2011 395
2012 412
2013 438
2014 417
2015 438
2016 500
2017 482
2018 505
2019 520
2020 556
2021 617
2022 667
2023 509
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

11,559 results

Results by year

Filters applied: . Clear all
Page 1
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, André V, Harbeck N, Martin M; monarchE Committee Members. Johnston SRD, et al. Among authors: martin m. Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6. Lancet Oncol. 2023. PMID: 36493792 Clinical Trial.
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.
Calsina B, Piñeiro-Yáñez E, Martínez-Montes ÁM, Caleiras E, Fernández-Sanromán Á, Monteagudo M, Torres-Pérez R, Fustero-Torre C, Pulgarín-Alfaro M, Gil E, Letón R, Jiménez S, García-Martín S, Martin MC, Roldán-Romero JM, Lanillos J, Mellid S, Santos M, Díaz-Talavera A, Rubio Á, González P, Hernando B, Bechmann N, Dona M, Calatayud M, Guadalix S, Álvarez-Escolá C, Regojo RM, Aller J, Del Olmo-Garcia MI, López-Fernández A, Fliedner SMJ, Rapizzi E, Fassnacht M, Beuschlein F, Quinkler M, Toledo RA, Mannelli M, Timmers HJ, Eisenhofer G, Rodríguez-Perales S, Domínguez O, Macintyre G, Currás-Freixes M, Rodríguez-Antona C, Cascón A, Leandro-García LJ, Montero-Conde C, Roncador G, García-García JF, Pacak K, Al-Shahrour F, Robledo M. Calsina B, et al. Among authors: martin mc. Nat Commun. 2023 Feb 28;14(1):1122. doi: 10.1038/s41467-023-36769-6. Nat Commun. 2023. PMID: 36854674 Free PMC article.
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.
Criscione SW, Martin MJ, Oien DB, Gorthi A, Miragaia RJ, Zhang J, Chen H, Karl DL, Mendler K, Markovets A, Gagrica S, Delpuech O, Dry JR, Grondine M, Hattersley MM, Urosevic J, Floc'h N, Drew L, Yao Y, Smith PD. Criscione SW, et al. Among authors: martin mj. NPJ Precis Oncol. 2022 Dec 27;6(1):95. doi: 10.1038/s41698-022-00337-w. NPJ Precis Oncol. 2022. PMID: 36575215 Free PMC article.
Pearson syndrome.
Tedjaseputra A, Radhakrishnan K, Martin M, Downie P, Stergiotis M, Bain BJ. Tedjaseputra A, et al. Among authors: martin m. Am J Hematol. 2023 Mar;98(3):527-528. doi: 10.1002/ajh.26794. Epub 2022 Dec 5. Am J Hematol. 2023. PMID: 36436195 No abstract available.
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.
Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS, Stroyakovskiy D, Xu B, Moroose RL, Loi S, Visco F, Bee-Munteanu V, Afenjar K, Fresco R, Taran T, Chakravartty A, Zarate JP, Lteif A, Hortobagyi GN. Slamon DJ, et al. Among authors: martin m. Ther Adv Med Oncol. 2023 May 29;15:17588359231178125. doi: 10.1177/17588359231178125. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37275963 Free PMC article.
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
Guerrero-Zotano Á, Belli S, Zielinski C, Gil-Gil M, Fernandez-Serra A, Ruiz-Borrego M, Ciruelos Gil EM, Pascual J, Muñoz-Mateu M, Bermejo B, Margeli Vila M, Antón A, Murillo L, Nissenbaum B, Liu Y, Herranz J, Fernández-García D, Caballero R, López-Guerrero JA, Bianco R, Formisano L, Turner N, Martín M. Guerrero-Zotano Á, et al. Among authors: martin m. Clin Cancer Res. 2023 Apr 14;29(8):1557-1568. doi: 10.1158/1078-0432.CCR-22-2206. Clin Cancer Res. 2023. PMID: 36749874 Free PMC article. Clinical Trial.
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
de Haas SL, Slamon DJ, Martin M, Press MF, Lewis GD, Lambertini C, Prat A, Lopez-Valverde V, Boulet T, Hurvitz SA. de Haas SL, et al. Among authors: martin m. Breast Cancer Res. 2023 Jan 11;25(1):2. doi: 10.1186/s13058-022-01587-z. Breast Cancer Res. 2023. PMID: 36631725 Free PMC article. Clinical Trial.
11,559 results
You have reached the last available page of results. Please see the User Guide for more information.